Diversified Trust Co Has $2.69 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Diversified Trust Co reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 11.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 28,177 shares of the medical research company’s stock after selling 3,538 shares during the period. Diversified Trust Co’s holdings in Edwards Lifesciences were worth $2,693,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. DSM Capital Partners LLC bought a new position in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. Turtle Creek Wealth Advisors LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $34,000. Riverview Trust Co bought a new position in Edwards Lifesciences in the 1st quarter valued at about $34,000. Pingora Partners LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $38,000. Finally, SRS Capital Advisors Inc. boosted its holdings in shares of Edwards Lifesciences by 292.6% during the third quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after acquiring an additional 474 shares during the period. Institutional investors own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

EW has been the subject of several research reports. Oppenheimer lifted their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. Royal Bank of Canada upped their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a research note on Monday, April 15th. Citigroup raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $98.00 to $105.00 in a report on Wednesday, May 22nd. Mizuho raised their target price on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a “buy” rating in a report on Thursday, April 11th. Finally, StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Thursday, June 27th. One analyst has rated the stock with a sell rating, five have given a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $95.06.

Edwards Lifesciences Stock Down 2.3 %

EW stock opened at $90.23 on Tuesday. The firm has a 50-day moving average price of $87.85 and a 200-day moving average price of $85.37. Edwards Lifesciences Co. has a 12 month low of $60.57 and a 12 month high of $96.12. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $54.37 billion, a P/E ratio of 38.89, a price-to-earnings-growth ratio of 3.38 and a beta of 1.11.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.64 by $0.02. The business had revenue of $1.60 billion during the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities research analysts anticipate that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insider Activity at Edwards Lifesciences

In other news, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $92.42, for a total value of $2,712,527.00. Following the completion of the transaction, the director now owns 4,486 shares of the company’s stock, valued at $414,596.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In related news, CEO Bernard J. Zovighian purchased 580 shares of Edwards Lifesciences stock in a transaction on Monday, May 6th. The shares were purchased at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the transaction, the chief executive officer now owns 3,268 shares of the company’s stock, valued at approximately $280,198.32. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Michael A. Mussallem sold 29,350 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $92.42, for a total value of $2,712,527.00. Following the transaction, the director now owns 4,486 shares of the company’s stock, valued at $414,596.12. The disclosure for this sale can be found here. Insiders have sold a total of 119,849 shares of company stock valued at $10,579,038 in the last 90 days. 1.27% of the stock is owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.